{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(3)"],"submitter":["Gubareva LV"],"pubmed_abstract":["The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4-10-fold reduced susceptibility to baloxavir."],"journal":["Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6344838"],"repository":["biostudies-literature"],"pubmed_title":["Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons."],"pmcid":["PMC6344838"],"pubmed_authors":["Patel MC","Wentworth DE","Barnes J","Mishin VP","Nguyen HT","Fry AM","Gubareva LV","Sinner M","Katz JM","Chesnokov A","Reid H","Spencer S","Garten R","Campbell AP","De La Cruz J"],"additional_accession":[]},"is_claimable":false,"name":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.","description":"The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4-10-fold reduced susceptibility to baloxavir.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jan","modification":"2025-04-25T23:29:02.113Z","creation":"2019-03-26T22:53:12Z"},"accession":"S-EPMC6344838","cross_references":{"pubmed":["30670144"],"doi":["10.2807/1560-7917.ES.2019.24.3.1800666"]}}